[Current status and issues of clinical development of novel anti-diabetic drugs].
Clinical development of new antidiabetic drugs such as SGLT2 inhibitor, GPR40 agonist, GPR119 agonist, and GKA has been progressing world wide. Action mechanism of each drug is unique and clearly distinguished from the existing drugs. The effect of SGLT2 inhibitors is independent of insulin action and characterized by inhibition of glucose reabsorption in the kidney accompanying with significant body weight reduction. It is known that GPR40 agonist stimulates insulin secretion in glucose independent manner. GKA potentiates glucose-stimulated insulin secretion from pancreatic beta cells and stimulates glucose uptake into the liver. Selective SGLT2 inhibitors and GPR40 agonist are expected to enter into the market in near future.